Board at its meeting held today, i.e. May 11, 2026 has, inter alia, considered and approved the following: (i) audited Standalone and Consolidated Financial Results along with Audit Reports ....
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.0 pts less than Nifty Microcap 250 and 4.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Corona Remedies reported audited standalone FY2026 results with revenue from operations of Rs. 1,403.18 Crores, up 17.3% from Rs. 1,196.42 Crores in FY2025. Net profit after tax grew 24% to Rs. 184.85 Crores from Rs. 149.05 Crores. Basic EPS stands at Rs. 30.22 vs Rs. 24.37 in prior year. The board declared a final dividend of Rs. 10 per share (100% payout), subject to shareholder approval at AGM on June 19, 2026 record date. An exceptional item of Rs. 19.10 Crores was recorded due to one-time impact of new Labour Codes. The company also recommended appointing Walker Chandiok & Co LLP as new statutory auditor for 5 years, replacing Deloitte. The shares were listed on NSE/BSE in December 2025 via IPO.
Strong profitability growth with 24% PAT increase signals solid operational performance. The clean audit opinion with unmodified reports is positive for investor confidence. Dividend declaration provides immediate shareholder回报. The auditor change may indicate strategic review of audit approach.